Clinical trials: Diabetes Type 1
Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.
German Multi-centered, randomized, crossover study in diabetic patients evaluating two infusion sets under real life conditions at home.
- Trial name
- NCT02103595
- Testing
- Accu-Chek FlexLink, Accu-Chek FlexLink Plus
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 1
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes
This trial is conducted in Asia and Oceania. The aim of this trial is to compare the efficacy and safety of human insulin produced by the current process and the NN729 process in type 1 diabetes.
- Trial name
- NCT00569400
- Testing
- human insulin
- Where
- 15 sites in Australia, Hong Kong and 2 more
- Volunteers
- 241 people
- Sponsor
- Novo Nordisk A/S
Diabetes
SKAMo-2: the Real-life Test of Continuous Photoacoustic Signal by Neogly in Patients With Type I Diabetes
Diabetes is one of the very common and chronic diseases in the present world, which affects children and adults. Diabetes is characterized by hyperglycemia.
- Trial name
- NCT06035367
- Testing
- Non-invasive continuous monitoring device to record photoacoustic signal
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Eclypia
Atherosclerosis, Cardiovascular Disease
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
To evaluate the safety, tolerability, PK and immunogenicity of single and multiple ascending doses of MEDI6570 in subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT03654313
- Testing
- MEDI6570
- Where
- 9 sites in United States
- Volunteers
- 88 people
- Sponsor
- MedImmune LLC
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Type 2 Diabetes
GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104…
- Trial name
- NCT00252876
- Testing
- tesaglitazar
- Where
- 277 sites in United States, Argentina and 29 more
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of the Performance and Use of Non-Invasive Glucose Monitoring Device
Diabetes is a leading cause of death in the Western World with medical costs increasing annually. There is no cure for diabetes, and blood glucose monitoring is a key component in diabetes treatment and management.
- Trial name
- CR-01-001 (NCT00889668)
- Testing
- GlucoTrack
- Where
- Israel
- Volunteers
- 180 people
- Sponsor
- Integrity Applications Ltd.
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1…
- Trial name
- onset®7 (NCT02670915)
- Testing
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Where
- 155 sites in United States, Bulgaria and 16 more
- Volunteers
- 834 people
- Sponsor
- Novo Nordisk A/S
Type1diabetes
Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.
This is a study of the Minimed 670G 4.0 insulin pump, assessing the efficacy of the Advanced Hybrid Closed Loop (AHCL) algorithm in controlling blood glucose levels in Type 1 Diabetes.
- Trial name
- NCT04073576
- Testing
- AHCL, SAP+PLGM
- Where
- New Zealand
- Volunteers
- 60 people
- Sponsor
- Christchurch Clinical Studies Trust Ltd
Diabetes Mellitus, Type 1
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1…
- Trial name
- IOOZ (NCT00487240)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Levemir
- Where
- 28 sites in United States, Argentina and 7 more
- Volunteers
- 387 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes
The primary objective of the current study was to investigate the safety and tolerability of BI 1356 BS following administration of multiple rising oral doses of 1 mg, 2.5 mg, 5 mg, and 10 mg over 12 days in male patients with…
- Trial name
- NCT02183350
- Testing
- BI 1356 BS - single rising dose
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
The purpose of this study is to test for superiority in improvements from baseline in patient reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin glargine plus rapid acting insulin glulisine MDI…
- Trial name
- NCT00135941
- Testing
- insulin glargine, insulin glulisine
- Where
- United States
- Volunteers
- 582 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
The purpose of this study is to collect information on how NovoPen® 6 works with Tresiba® \& Fiasp® for treatment of people with type 1 diabetes and see if the use of NovoPen® 6 can help participants achieve better blood sugar…
- Trial name
- CONNECT 1 (NCT05069545)
- Testing
- Insulin degludec, Fast-acting insulin aspart
- Where
- 26 sites in Belgium, Denmark and 2 more
- Volunteers
- 411 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr.
- Trial name
- NCT05422053
- Testing
- t:slim X2 insulin pump with Control-IQ technology 1.5
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of the trial is to evaluate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the trial drug on the body) properties of FIAsp…
- Trial name
- NCT01934712
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Local Registration Trial in China Humalog Mix 50
The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in insulin-requiring diabetic patients treated twice daily with human insulin mix 50/50, versus the 2-hour PPBG excursion…
- Trial name
- NCT00191581
- Testing
- Humalog Mix 50, Human Insulin Mix 50:50
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet…
- Trial name
- NCT00308139
- Testing
- exenatide, long acting release, exenatide
- Where
- 25 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM
This is a Phase 1, open-label, sequential, multiple-dose, drug-drug interaction study of GK activator HMS5552 and metformin in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02597400
- Testing
- Metformin, HMS5552
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hua Medicine Limited